HighTower Advisors
MDGL icon

HighTower Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

HighTower Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-600
Closed -$70.8K – 3858
2023
Q4 		$70.8K Buy
+600
New +$105K ﹤0.01% 3258

Other funds holding MDGL

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $54.9B AUM 27.38% 1-Year Est. Return

HighTower Advisors's MDGL Position: Q3 2026 in Review

HighTower Advisors reduced its Madrigal Pharmaceuticals (MDGL) stake by 5.5% in Q3 2026, selling an estimated $353K and leaving 11,396 shares worth $5.74M. The position accounts for 0.01% of the portfolio, ranked #1182.

HighTower Advisors first reported a position in MDGL in Q4 2022 and has held it in 13 quarters since. The position peaked at $7.28M in Q1 2026. 332 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • HighTower Advisors held 11,396 shares of Madrigal Pharmaceuticals worth $5.74M as of Q3 2026.
  • HighTower Advisors sold 667 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $353K.
  • Madrigal Pharmaceuticals made up 0.01% of HighTower Advisors's portfolio in Q3 2026, its #1182 holding.
  • HighTower Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
  • HighTower Advisors's Madrigal Pharmaceuticals position peaked at $7.28M in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.